Both situations require a written refund request within 28 days of the original payment date, submitted to [email protected]
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: A randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
In early clinical trials, patients on GLP-1 agonists have achieved weight loss of 1520%, compared to the 510% typically seen with previous medications. Holistic approach to GLP-1 drugs Beyond weight loss, GLP-1 agonists have demonstrated the ability to reduce major cardiovascular events, combat fatty liver disease and alleviate obesity-related complications such as knee pain, sleep apnea, and acid reflux
[21] [22] Regarding GLP-1 medications and lymphoedema , there is currently insufficient evidence to recommend their use specifically for this condition
Look AHEAD Research Group, Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, et al